ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Rate of resistance to second-line drugs for countries with high burden of multidrug-resistant tuberculosis

Rate of resistance to second-line drugs for countries with high burden of multidrug-resistant tuberculosis
  Year Method* MDR-TB cases tested for second-line drug resistance XDR cases among MDR-TB cases tested Proportion of MDR cases that were XDR (percent)
Armenia 2007 Survey 199 8 4 (1.8-7.8)
Azerbaijan, Baku 2007 Survey 431 55 12.8 (9.8-16.3)
BangladeshΔ 2008 Surveillance 168 1 0.6
China 2008 Survey 270 30 11.1 (7.6-15.5)
Estonia 2008 Surveillance 72 9 12.5
Georgia 2006 Survey 70 3 4.3 (0.9-12)
India, Gujarat state 2006 Survey 216 7 3.2 (1.2-6.6)
Kazakhstan 2008 Surveillance 373 16 4.3
Latvia 2008 Surveillance 128 19 14.8
Lithuania 2003 to 2006 Surveillance 173 25 14.5
Moldova 2006 Survey 47 3 6.4 (1.3-17.5)
Russia, Tomsk oblast 2003 to 2005 Surveillance 458 30 6.6
South Africa 2008 Surveillance 5451 573 10.5
Tajikistan, Dushanbe and Rudaki 2009 Survey 100 21 21 (13.5-30.3)
Ukraine, Donetsk oblast 2006 Survey 20 3 15 (3.2-37.9)
Data are n or % (95% CI).
MDR: multidrug resistant; TB: tuberculosis; XDR: extensively drug resistant.
* Data derived from continuous surveillance systems versus from periodic drug-resistance surveys.
¶ Countries with a high burden of tuberculosis, for which representative data for prevalence of XDR disease were available; XDR prevalence data were not available for any of the remaining high-burden countries.
Δ Damien Foundation Area, previously treated cases only.
Reproduced from: Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830. Illustration used with the permission of Elsevier Inc. All rights reserved.
Graphic 56811 Version 5.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟